PharmGen Science Inc

PharmGen Science Inc exhibits a strong liquidity position with a current ratio of 2.85, indicating the company can cover its short-term liabilities more than two and a half times over with its current assets. The company holds KRW 21.88 billion in cash and equivalents, which is a significant portion of its total assets of KRW 195.41 billion. However, the company's free cash flow is negative at KRW -114.80 billion, driven by a capital expenditure of KRW -2.67 billion and a net loss of KRW -116.66 billion. Profitability metrics are concerning, with a return on equity of -0.7974 and a return on assets of -0.597, both significantly below the industry median for pharmaceutical companies. The company reported an operating loss of KRW -127.35 billion and a net loss of KRW -116.66 billion, indicating a substantial decline in operational performance. Gross profit of KRW 111.68 billion is insufficient to cover operating expenses, contributing to the negative operating income. The company's revenue is primarily derived from pharmaceuticals and functional cosmetics, with a significant portion of its business concentrated in the domestic Korean market. While the company does export products, the input data does not provide specific geographic revenue breakdowns. The lack of detailed segment reporting limits the ability to assess geographic diversification and exposure to regional economic risks. Growth trajectory is negative, with the company reporting a net loss and negative free cash flow. The outlook for the current fiscal year is not explicitly provided, but the financial performance suggests a challenging operating environment. The company's capital expenditures are modest, but the negative free cash flow indicates that the company is not generating sufficient cash to fund operations and investments without external financing. Risk factors include a low liquidity risk score, but the company's negative operating and net income pose a significant credit risk. The debt-to-equity ratio is low at 0.04, suggesting minimal leverage, but the company's profitability issues could lead to increased debt in the future. There are no immediate filing-based liquidity or dilution flags, but the negative free cash flow and operating loss could lead to dilution if the company requires additional capital. Recent events include the company's transition from Wooridul Pharmaceutical Ltd to PharmGen Science Inc, which may indicate a strategic rebranding or restructuring. The company's 10-K filings and other disclosures do not mention any significant recent events that would impact its financial position or operations. The absence of recent dilutive events and the low dilution risk score suggest that the company is not currently under pressure to issue new shares.